Pain Management

Individuals who have chronic widespread pain showed a 75% increased risk of developing hypertension compared to fellow UK Biobank participants who were pain-free.

Undertreated acute pain can lead to life-long chronic pain but there are still few effective opioid-sparing options. A new review reinforces the persistent safety issues.

Vertanical's VER-01 shows promise in reducing chronic low back pain, outperforming opioids and maintaining relief for over a year.

Opioids are still prescribed to 1 in 5 US adults with chronic pain because effective alternatives are not available; the FDA guidance supports enhanced research paradigms.

Your daily dose of the clinical news you may have missed.

The US FDA approved Tonmya, a groundbreaking treatment for fibromyalgia, offering hope to millions experiencing chronic pain and sleep issues.

The NaV1.8 ion channel inhibitor was planned as a follow-up to the company's first nonopioid for acute pain, suzetrigine, approved by the FDA in January 2025.

The FDA requires all manufacturers of opioid pain medications to revise labeling to emphasize and explain risks with long-term use.

For the often treatment-resistant pain of neuropathic conditions, the meta-analysis includes updated evidence for both pharmacologic and neuromodulatory interventions.

Dr Khanna breaks down the bidirectional relationship and explains why standard pain management often falls short for people with obesity.